Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Slam Biel Dunk, Nothing But Net!!
Now What OTHER Recycled BS Comes Our Way Next!!
Probably The Standard YEAH BUT!!
Hehehehehe!!
Well, Actipatch > Cox-2 Inhibitors, > Opioids
Those Cox-2's Are Considered Far SUPERIOR To Opioids.
LOL!! Obfuscation!! Point Is SUPERIOR To Opioids!!
The Cox-2 Used In The Study Is Considered Too Powerful.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975651/
CLUE: The Cox-2 Inhibitor Used Can't Be Sold
In America.
Why??
TOO POWERFUL!!
More Powerful Than Opioids.
FDA~~~ "Results Indicate that ActiPatch Significantly Reduced Pain"
510k Number - K192234
Device Name - ActiPatch
Indications for Use - Adjunctive treatment of Musculoskeletal Pain
Clinical Data:
The clinical data in this 510(k) includes results from three IRB approved, randomized, controlled studies. Additionally, usability testing was conducted to support the OTC use of the device.
* A randomized, controlled trial on chronic cervical osteoarthritis (neck pain): This was a randomized, active-treatment controlled study to evaluate the safety and effectiveness of the ActiPatch medical device to reduce the pain level of patients diagnosed with cervical osteoarthritis. The active-treatment control was an NSAID of the Cox-2inhibitor family. There were 200 intent-to-treat patients, out of which 197 completed the four-week study. There were 142 women (71%) and 58 (29%) men in the study, with an average age of 45 years. The primary endpoint for efficacy was reduction in pain (VAS score) while at rest and being active, over four weeks, when compared to the beginning of the study. The results indicate that ActiPatch significantly reduced pain (measured by VAS pain) associated with COA in the device treatment group, and that the treatment differences between device-treatment and NSAID-treatment groups was significant (p<0.05).
* A randomized controlled trial on osteoarthritis of the knee: The osteoarthritis of the knee study was a double-blinded, randomized, placebo-controlled study to evaluate the safety and effectiveness of the ActiPatch medical device to reduce the pain level of patients diagnosed with knee osteoarthritis. The placebo treatment was a device that was identical to ActiPatch but did not produce an
electromagnetic field when turned on. There were 66 intent-to-treat patients, out of which 60 patients completed the four-week study. There were 43 women (71.6%) and 17 (16.4%) men in the study, with the following average demographics at baseline: 68 years of age, BMI of 27.4 and disease duration of 12.1 years. The primary effectiveness endpoints were improvements in pain level over the four weeks as measured by the before and after VAS score and WOMAC scores, and the primary safety endpoint was all treatment-related adverse events during the study. The results indicate that ActiPatch significantly reduced pain (measured by VAS pain) associated with KOA in the device treatment group, and that the treatment differences between active and placebo treatment groups was significant (p<0.05).
• A randomized controlled trial on plantar fasciitis (heel pain): This was a randomized, double-blinded, placebo-controlled study to evaluate the safety and effectiveness of the ActiPatch medical device to reduce the pain level of patients diagnosed with plantar fasciitis. The placebo treatment was a device that was identical to ActiPatch but did not produce an electromagnetic field when turned on. A total of 70 patients were recruited into the study, and all 70 completed the study. There were 52 women (74.4%) and 18 (25.6%) men in the study, with the following average demographics at baseline: 51.5 years of age, BMI of 31.8 and disease duration of 1.1 years. The primary effectiveness endpoint was the daily morning (AM) VAS score, and the primary safety endpoint was all treatment-related adverse events during the 7-day study. The results indicate that ActiPatch significantly reduced pain (measured by VAS pain) associated with PF in the device treatment group, and that the treatment differences between active and placebo treatment groups was significant (p<0.05).
Conclusion: The non-clinical data, clinical data, and extensive real-world registry data demonstrate that the ActiPatch is at least as safe and effective as the predicate device and can be used as an over-the-counter device for adjunctive treatment of musculoskeletal pain.
https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192234.pdf
Credit to srin!!
Cox-2 Is An NSAID STRONGER Than Opioids.
Actipatch Won!!
~~~~~~~ FALSE INFORMATION !! ~~~~~~~
The Opioid Studies For Biel Have Been Posts Dozens Of Times.
Actipatch Was Superior To A Cox 2 Opioid Deemed To Strong
For Sale In America.
Lousy $12,000 Is All Left At $.0006
Unless Someone Else Adds To The Ask.
Damn Near Took Them Myself Today,
Even Though I Have PLENTY Of Shares!!
Distributors/Pharma Suggest You Jump Hard On This Now
Since The Passage Of The #nopainact !!
MONSTER!!
Semantics
LOL!! Here Is Your Quote.
"Nope, KT is not a distributor, they are an OEM re-seller"
KT Is A Distributor.
Semantics.
https://smallbusiness.chron.com/oem-distributor-process-work-36169.html
Like Umm, KT Tape!! lol
10-Million-Units-A Year-Puts A Nickel In The Rearview-Mirror!!
That Is Worldwide!!
Totally Wrong!! FACT!!
No Reason To State Biel On Website.
Is A Customer And Distributor.
Biel!!
MONSTER!!
LOL!! Those "Folks" Are A Distributor And Customer.
Distributors/Pharma Suggest You Jump Hard On This Now
Since The Passage Of The #nopainact !!
MONSTER!!
LOL!! That Is Biel Products!! Feel Free To-Buy-Them!!
Again China Was Under Lockdown Where Biel Is MFG'ed
And Shipped.
Umm, New KT Packaging Coming.
Recently Announced.
Flase Again. The Biel Update Was Internationally Available
And Was Made Available To All That Wanted On The Zoom Call.
It Was An Update.
LOL!! ~~~~~ UTTER NONSENSE!! ~~~~~ LOL!!
LOL!! $5500 Is Selling?? More $ Buying!!
6's Gone Soon Enough then 7's
Peeps Waiting For The Upward Price Explosion.
Umm, Gonna Need To Slap The Ask!!
Few Biel Shares Available For Sale!!
We Longs KNOW How Well Actipatch/RecoveryRX Works.
We have used them and continue to use them and many of us are Truly Amazed.
Pain ANYWHERE, Put An Actipatch On It.
Many of us have substantially reduced or eliminated OTC pain relievers.
We longs know that TENS Units are not even close to the effectiveness of Actipatch.
We know that it works for dozens and dozens of issues.
We know it reduces substantially injury recovery time.
We longs believe we are sitting on a massive power keg, should this product take off as we believe.
With the right and proper marketing I believe returns here could be totally mind numbing.
This Product is too good to be allowed to fail.
Never used one? Buy it, try it, You most probably will become a believer.
RecoveryRX Reduces Opioids 50% Or Better
~~~~~~~ #nopainact ~~~~~~~
NO PAIN ACT update! #noopioids #opioidcrisis https://t.co/RkRo0HnBjs
— BioElectronics Corporation (@BielCorp) December 28, 2022
Newbies, Make Sure You Read This Post, Linked.
Blows The Door Open IMO.
They Are Today Trying To Hire A Specialist As A Result.
This Can Be A Door Buster.
~~~~~~~ #nopainact ~~~~~~~ Huge News!!
Under current law, hospitals receive the same payment from Medicare regardless of whether a physician prescribes an opioid, or a non-opioid. As a result, hospitals rely on opioids, which are typically dispensed by a pharmacy after discharge at little or no cost to the hospital. The NOPAIN Act would change this policy by directing the Centers for Medicare and Medicaid Services (CMS) to provide separate Medicare reimbursement for non-opioid treatments used to manage pain in both the hospital outpatient department (HOPD) and the ambulatory surgery center (ASC) settings. U.S. Representatives Terri Sewell (D-AL) and David McKinley (R-WV) led companion legislation in the House.
We Longs KNOW How Well Actipatch/RecoveryRX Works.
We have used them and continue to use them and many of us are Truly Amazed.
Pain ANYWHERE, Put An Actipatch On It.
Many of us have substantially reduced or eliminated OTC pain relievers.
We longs know that TENS Units are not even close to the effectiveness of Actipatch.
We know that it works for dozens and dozens of issues.
We know it reduces substantially injury recovery time.
We longs believe we are sitting on a massive power keg, should this product take off as we believe.
With the right and proper marketing I believe returns here could be totally mind numbing.
This Product is too good to be allowed to fail.
Never used one? Buy it, try it, You most probably will become a believer.
China Locked Down Is An Excuse?? LMAO!!
Biel Could Not Ship Nor Manufacture.
China Was Locked Down Tight.
Umm, China Was Shut Down Last Quarter
For MFG and Shipping.
No Longer An Issue Now.
Yes. I Would Pay That And More
If I Was In Position To Be Able To Do So!!
Biel Can Be Many Many Billions In Market Cap
With Great Marketing And Sales.
Hehehehehe!! Do The Math On 10 Million Unit
Sales Per Year!!
$.05 Is In The Rearview Mirror.
Umm, FULLY Diluted!!
$.01 Takes VERY FEW Sales To Get There
And That Includes Full Dilution.
Do The Math!!
Biel!!
MONSTER!!
Big Runs Coming 2023!!